MRX-2843 Inhibitor

Name: MRX-2843 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5755230
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755230

MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3nM and 0.64nM, respectively). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

MRX-2843, Inhibitor

Full Product Name

MRX-2843

Product Gene Name

MRX-2843, inhibitor

Product Synonym Names

UNC2371

Form/Format

Solid. Powder

Purity/Purification

99.51%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

488.67

Solubility

DMSO: 26.25mg/ml (53.72mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C29H40N6O

SMILES

CN1CCN(CC2=CC=C(C=C2)C2=CN([C@H]3CC[C@H](O)CC3)C3=NC(NCCC4CC4)=NC=C23)CC1

CAS Number

1429882-07-4

Target & IC50

MERTK: ic50 1.3nM
FLT3: ic50 0.64nM

Product Categories/Family for MRX-2843, inhibitor

Angiogenesis; FLT; Tyrosine Kinase/Adaptors

Product References and Citations for MRX-2843, inhibitor

Minson KA, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
Minson KA, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
Dan, Yan, Rebecca,et al. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2018.
Dan, Yan, Rebecca,et al. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2018.

Other Notes

Small volumes of MRX-2843, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for MRX-2843 purchase

MBS5755230 is an inhibitor targeting MRX-2843.